Taiho Pharmaceutical Co., Ltd.January 26, 2024

FDA 483 - Taiho Pharmaceutical Co., Ltd. - January 26, 2024

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Taiho Pharmaceutical Co., Ltd.

Record Details

An FDA inspection of Taiho Pharmaceutical Co., Ltd., a bulk drug manufacturer in Itano-Gun, Tokushima, Japan, revealed significant deficiencies in equipment maintenance and laboratory controls. Inspectors observed that corroded equipment was used for an extended period without proper investigation or justification, impacting tablet manufacturing. Additionally, the firm failed to perform adequate growth promotion testing for microbial media used in product testing.

Company: Taiho Pharmaceutical Co., Ltd.
Inspection Date: January 26, 2024
Product Type: Drugs
Office: Office of Biological Products Operations - Division I
Person: Nicholas L. Hunt (Senior CSO, Investigator)

Open in Dashboard

ID · 3ae477b2-2913-43d2-a8ab-92d073f60c3b